Major response to imatinib mesylate in KIT-mutated melanoma

J Clin Oncol. 2008 Apr 20;26(12):2046-51. doi: 10.1200/JCO.2007.14.0707.

Authors

F Stephen Hodi¹, Philip Friedlander, Christopher L Corless, Michael C Heinrich, Suzanne Mac Rae, Andrea Kruse, Jyothi Jagannathan, Annick D Van den Abbeele, Elsa F Velazquez, George D Demetri, David E Fisher

Affiliation

¹ The Melanoma Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 18421059
DOI: 10.1200/JCO.2007.14.0707

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Anastomosis, Surgical / adverse effects
Antineoplastic Agents / therapeutic use*
Benzamides
Female
Humans
Imatinib Mesylate
Melanoma / drug therapy*
Melanoma / genetics
Melanoma / surgery
Mutation
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / surgery
Neoplasm Seeding
Piperazines / therapeutic use*
Proto-Oncogene Proteins c-kit / genetics*
Pyrimidines / therapeutic use*
Rectal Neoplasms / drug therapy*
Rectal Neoplasms / genetics
Rectal Neoplasms / surgery

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Proto-Oncogene Proteins c-kit